Hai Zheng Pharmaceutical industry: subsidiaries produce vancomycin

The company is gradually from the API production enterprises to upgrade to the preparation of products, strategic layout is quite clear "as far as I know, the company does not have the production batch for hoop, as Vancomycin is a joint-venture subsidiary in the production, the company itself does not produce this drug." August 19, Hai Zheng Pharmaceutical Co., 600267.　　SH) Securities representative Dengjiufa said in an interview with the first financial news reporter. Rumors have been circulating in the capital markets this week that the sea is producing antibiotics to fight superbugs.　　It is said that both hoop and vancomycin for the treatment of super bacteria effective, and the sea is the pharmaceutical industry is "the only hoop, vancomycin listed companies." However, this claim has been denied by the maritime pharmaceutical industry. "I haven't seen the batch number for hoop so far, but Vancomycin is produced by our joint-venture subsidiaries, which are controlled by foreign investors," he said.　　"Dengjiufa said. The foreign company he is talking about is actually Hong Kong's Accor company. June 8, 2008, Hai Zheng Pharmaceutical and Accor signed a joint venture letter of intent, a total of 50 million U.S. dollars mainly engaged in vancomycin and other raw materials production and sales.　　The technology of vancomycin comes from Jalles, with a 49% stake in the sea. "Vancomycin production and sales are done by subsidiaries, basically for export, our company itself does not produce this product."　　Said the company. The reporter learned that, long before the concept of super bacteria, the sea is the performance of the pharmaceutical industry has been quite strong.　　The company's share price rose from July 2 to a maximum of 35.46 yuan, as of August 20, during which up to 26.06%. Corresponding to the strong share price is the first half of the company's performance is indeed good.　　Data show that the first half of the company to achieve the main business income of 2.113 billion yuan, an increase of 19%, to achieve net profit of 149 million yuan, the year-on-year growth of 40%, earnings per share 0.31 yuan.　　For this performance, the company in the interview to express satisfaction, "basically reached the beginning of the target." In addition, the company recently announced a targeted additional plans. The proposed non-public offering of shares does not exceed 61 million shares, the total amount of funds raised does not exceed 1.365 billion yuan, the issue price is not less than 22.53 yuan/share.　　The collection of funds will be mainly used in the subsidiary company Hai Zheng Pharmaceutical (Hangzhou) Co., Ltd. Fuyang preparation export base construction project.　　Analysts believe that Fuyang production base is the main engine of growth in the future profits, there will be new production lines in the year to put into production. "In the short term, the company will bring pressure to the shareholders of the two-tier market in the sea, but in the long term, it will bring positive benefits to the companies."　　Xiang Wealth Securities analyst Liying GUI thinks.　　Societe Generale Securities that the private issue of shares, although there is a certain dilution of earnings per share, but because the company is in the critical period of industrial upgrading, capital investment, the smooth financing will reduce the company's assets and liabilities rate, solvency will be promoted, conducive to the long-term development of the company. Fact, and the concept of super bacteria, in the long run, the company's main point is that the company is one of the leading domestic drug production, this year gradually from the raw material production enterprise upgrade to the preparation products, strategic layout is quite clear. It is understood that since 2007 the Sea is vigorously developing domestic preparation business, preparations in the company's operating income and gross profit accounted for more and more high, 2009 of the contribution of the preparation of more than 50%.　　The company has changed the pattern of raw drug exports in the past, the implementation of raw materials and preparations go hand in hand, the increase in international cooperation and preparation of production lines will accelerate the upgrading of the company's industrialization. It is worth mentioning that the sea is in fact the pharmaceutical industry has long been the pursuit of Chinese funds. Up to the two quarter, China's four funds to occupy the company's top ten circulating shareholders, the total shareholding of 31.4111 million shares, compared to the first quarter of 20.11 million shares, increase 11.3011 million shares, overweight most obvious.　　In addition, China's leading enterprises, the broad Fund and other funds are also in the two quarter of overweight. Risk tip: The increase in the size of the non-corporate drug sales brought about the risk of receivables, the relatively high debt ratio may bring financial pressure rise.